中文版正在生成中，先为你展示英文版分析。
AI核心结论
IDEXX Laboratories delivered strong Q1 FY2026 results with revenue of $1.14B (+14.3% YoY) and net income of $278.4M (+14.7% YoY), driven by expanding gross margins and solid operating cash flow generation.
营业收入
$1.14B
同比 ++14.26%
每股收益（基本）
$3.50
同比 ++17.45%
毛利率
63.4%
同比 ++0.92%
营业利润
$362.59M
同比 ++14.55%
提交于 · 解读更新于 · 来源: SEC EDGAR 10-Q 原文
Idexx Laboratories (IDXX) Q1 FY2026 营收 $1.14B，同比增长 14.3%。 净利润 $278.45M，同比增长 14.7%，稀释每股收益 $3.47。 毛利率 63.4%。
Total revenue grew 14.3% YoY to $1.14B in Q1 FY2026 from $998.4M in the prior-year period, reflecting robust demand across IDEXX's diagnostics and veterinary software segments.
来源: Source: 10-Q Income Statement
Gross margin improved approximately 91 basis points YoY to 63.35% from 62.44%, indicating favorable product mix and operational leverage as revenue growth outpaced cost of revenue growth of 11.5%.
来源: Source: 10-Q Income Statement & Key Ratios
Operating income rose 14.5% YoY to $362.6M, with operating margin holding nearly flat at 31.78% vs. 31.70% prior year, demonstrating cost discipline even as R&D spending increased 11.4% YoY to $65.8M.
来源: Source: 10-Q Income Statement
Operating cash flow increased 11.9% YoY to $266.2M, while share buybacks declined 12.4% YoY to $351.0M, and long-term debt fell 33.3% YoY to $299.9M, reflecting a healthier balance sheet posture.
来源: Source: 10-Q Cash Flow Statement & Balance Sheet
Diluted EPS grew 17.2% YoY to $3.47 from $2.96, outpacing net income growth of 14.7%, likely reflecting the benefit of ongoing share repurchase activity reducing the share count.
来源: Source: 10-Q Income Statement
IDEXX's current ratio stands at approximately 1.12, meaning current assets only modestly exceed current liabilities of $1.30B. Current liabilities grew 14.4% YoY, faster than current assets (+10.4%), suggesting potential near-term liquidity pressure if business conditions deteriorate.
来源: Source: 10-Q Balance Sheet & Key Ratios
The debt-to-equity ratio of 1.18 indicates IDEXX carries more total liabilities than stockholders' equity, which could constrain financial flexibility. While long-term debt has been reduced by 33.3% YoY to $299.9M, total liabilities remain at $1.83B.
来源: Source: 10-Q Balance Sheet & Key Ratios
IDEXX repurchased $351.0M in shares during Q1 FY2026, significantly exceeding operating cash flow of $266.2M. This pace of capital return, if sustained, could pressure cash reserves or require additional borrowing.
来源: Source: 10-Q Cash Flow Statement
R&D expenses of $65.8M represent a meaningful portion of operating costs, and any slowdown in new product development or failure to commercialize innovations could impair IDEXX's competitive positioning in the veterinary diagnostics market.
来源: Source: 10-Q Income Statement
IDEXX's revenue is heavily concentrated in the companion animal veterinary diagnostics market, making it vulnerable to cyclical shifts in pet ownership trends, veterinary visit frequency, or macroeconomic pressures affecting discretionary pet healthcare spending.
来源: Source: 10-Q Income Statement (inferred from business model)
Q1 FY2026 实际 EPS $3.47，分析师一致预期 $3.47，超预期 +0.1%。
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
营业收入 | $1.14B | $998.43M | +14.26% |
营业成本 | $418.08M | $375.05M | +11.47% |
毛利润 | $722.74M | $623.38M | +15.94% |
营业利润 | $362.59M | $316.53M | +14.55% |
净利润 | $278.45M | $242.68M | +14.74% |
每股收益（基本） | $3.50 | $2.98 | +17.45% |
每股收益（稀释） | $3.47 | $2.96 | +17.23% |
研发费用 | $65.79M | $59.06M | +11.39% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
总资产 | $3.39B | $3.21B | +5.35% |
流动资产 | $1.45B | $1.32B | +10.36% |
总负债 | $1.83B | $1.77B | +3.61% |
流动负债 | $1.3B | $1.14B | +14.40% |
股东权益 | $1.56B | $1.45B | +7.46% |
现金及等价物 | $200.53M | $163.97M | +22.30% |
长期债务 | $299.85M | $449.8M | -33.34% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
经营活动现金流 | $266.25M | $237.96M | +11.89% |
投资活动现金流 | $-33.54M | $-29.61M | -13.29% |
筹资活动现金流 | $-211.43M | $-330.32M | +35.99% |
股票回购 | $351.04M | $400.89M | -12.44% |
折旧及摊销 | $37.68M | $34.06M | +10.63% |
| 指标 | 当期 | 上期 | 同比变化 |
|---|---|---|---|
毛利率 | 63.4% | 62.4% | +0.92% |
营业利润率 | 31.8% | 31.7% | +0.08% |
净利率 | 24.4% | — | — |
净资产收益率 | 17.9% | — | — |
总资产收益率 | 8.2% | — | — |
流动比率 | $1.119 | — | — |
资产负债率 | $1.176 | — | — |
IDEXX delivered strong Q1 FY2026 results with revenue of $1.14B, up 14.3% YoY, and net income of $278.4M, up 14.7% YoY. Diluted EPS came in at $3.47, a 17.2% increase from $2.96 in the prior-year period.
IDEXX's revenue growth of 14.3% YoY to $1.14B was driven by strong demand for its veterinary diagnostic products and services, with gross profit growing even faster at 15.9% YoY to $722.7M, indicating favorable product mix. Cost of revenue grew at a slower pace of 11.5%, contributing to gross margin expansion to 63.35%.
IDEXX's balance sheet shows total assets of $3.39B and stockholders' equity of $1.56B, with long-term debt reduced 33.3% YoY to $299.9M. The current ratio of 1.12 indicates adequate near-term liquidity, though current liabilities grew faster than current assets in the period.
IDEXX repurchased $351.0M in shares during Q1 FY2026, down 12.4% from $400.9M in the prior-year period. This buyback activity contributed to diluted EPS growth of 17.2%, which outpaced net income growth of 14.7%.
Key risks include IDEXX's heavy concentration in the companion animal veterinary diagnostics market, which exposes it to shifts in pet healthcare spending. Additionally, the current ratio of 1.12 and a debt-to-equity ratio of 1.18 suggest moderate financial leverage, and share buybacks of $351.0M exceeded operating cash flow of $266.2M, which could pressure liquidity if sustained.